# Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients

> **NCT01837277** · PHASE2,PHASE3 · COMPLETED · sponsor: **Fundação Bahiana de Infectologia** · enrollment: 186 (actual)

## Conditions studied

- Severely Immunocompromised HIV Patients

## Interventions

- **DRUG:** Dolutegravir 50 mg
- **DRUG:** Efavirenz-based regimens

## Key facts

- **NCT ID:** NCT01837277
- **Lead sponsor:** Fundação Bahiana de Infectologia
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-15
- **Primary completion:** 2021-07-31
- **Final completion:** 2021-09-30
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2023-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01837277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01837277, "Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01837277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*